Skip to main content
Top of the Page

SOHO Society News

SOHO Annual Meeting

Registration is open for SOHO 2022! The tenth annual meeting of the society, SOHO 2022, will be held as a hybrid event (in-person and virtual) on September 28-October 1, 2022. Advances in leukemia, lymphoma, myeloma, myeloproliferative neoplasms, myelodysplastic syndromes and related malignancies will be highlighted during the official educational program. For more information and to register, visit

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. The primary purpose of the SOHO meetings are to exchange the latest information in the hematologic oncology field. SOHO is the only global society that focuses solely on blood tumors. Importantly, SOHO meetings include outstanding leaders, innovators and budding young investigators that interact to stimulate progress in this important field.



Latest Clinical News

News-Blood Cancers Today

BCT RSS News Feed - Blood Cancers Today (BCT) delivers the latest news, education, and information relevant to hematologic oncology patients and practices, with important insights from experts in the field.

UCART20x22 Demonstrates Preclinical Activity of Allogeneic Dual CAR T Therapy Against NHL

The allogeneic dual CAR T-cell product UCART20x22 demonstrated pre-clinical proof of concept for patients with relapsed or refractory non-Hodgkin lymphoma.

IDH Mutation Location Affected Relapse Risk After AML Transplant

Certain IDH mutation locations had a higher association with risk of AML relapse after transplant.

Long-Term RESONATE-2 Data Show Sustained Survival Benefit of First-line Ibrutinib in CLL

With follow-up of up to eight years, the long-term results of the RESONATE-2 trial demonstrate sustained progression-free and overall survival with the use of first-line ibrutinib for chronic lymphocytic leukemia.

Neurotoxicity Acceptable in CD19 CAR-T Cell Therapy for B-ALL with CNS Leukemia

CD19-directed CAR-T cell therapy could induce similar high response rates in patients with B-cell acute lymphoblastic leukemia with central nervous system leukemia.

Risk for Neurologic Adverse Events Less with Immune Checkpoint Inhibitors

The use of immune checkpoint inhibitors is associated with a decreased likelihood of developing neurologic adverse events compared with other cancer medications, particularly cytotoxic chemotherapy.

Member Spotlight

Jennifer Brown

Jennifer R. Brown, MD, PhD | SOHO President 2023

The Board of Directors and the Steering committee of the Society of Hematologic Oncology are pleased to announce that Jennifer R. Brown, MD, PhD will assume the position of President-Elect effective September 28, 2022, and will serve as SOHO President in 2023.  

Dr. Brown has served on the SOHO Steering and Education committees since 2014. She also served as co-chair for the SOHO Highlights meeting in 2021. Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts. Dr. Brown completed a B.S. and M.S. simultaneously in molecular biophysics and biochemistry (MB&B) at Yale, graduating summa cum laude with distinction in MB&B.  She proceeded to Harvard Medical School where she received her MD and PhD in molecular genetics in 1998 and was awarded the James Tolbert Shipley Prize for research accomplishment in the graduating class.  She then served as an intern and resident in Internal Medicine at Massachusetts General Hospital followed by fellowship in Hematology and Medical Oncology at the Dana-Farber Cancer Institute. Dr. Brown joined the faculty of DFCI and Harvard Medical School in 2004, where she has an active clinical-translational research program in CLL. 

Her particular interests include the development of novel targeted therapeutics for CLL, as well as the genomics of CLL.  She has been instrumental in the clinical development of both idelalisib and ibrutinib, leading to their regulatory approvals in CLL.  In the area of genomics, she has been instrumental in the description of the somatic mutation profile of CLL and is now particularly interested in the implementation of genomic technology in the clinic, including for prognosis and targeted therapy.  She also has a longstanding research interest and focus on the inherited predisposition to CLL.  To date she has published over 150 papers in the scientific literature, predominantly in CLL.  She is an active member of the CLL Research Consortium and serves on the Alliance Leukemia and Leukemia Correlative Science Committees as well as the NIH Cancer Biomarkers Study Section.  In 2014 she was the recipient of two awards from Dana-Farber Cancer Institute, the Clinical Innovation Award, as well as the George Canellos Award for Excellence in Clinical Investigation and Patient Care.

Please join us in congratulating Dr. Brown!

CLML Journal Content

BCT News

Back to Top